A Hib vaccine battle with Haemophilus influenzae

Abstract

With nearly 386,000 deaths caused by Haemophilus influenzae reported by WHO, Haemophilus influenzae is one of the worst killers of children under the age of five. Nowadays, there are places still prone to invasive Hib infections, and numerous areas are still susceptible to Hib-related illnesses. Haemophilus influenza is a bacterium plaguing many families, particularly those with young children. However, antibiotic resistance is increasing. The Hib vaccine may be another solution. The prevalence of Hib infection has dropped significantly after the launch of Hib immunization. The Hib combination vaccination, however, does not protect against all bacterial types. Consequently, certain people may benefit from receiving medical therapy. However, at present, peoples understanding of Hib vaccine in many areas is still limited. This study present a thorough and critical evaluation of the most recent understanding of H.influenzae and the medication: Hib vaccine. The focus of this review is to provide an overview of current research on Haemophilus influenzae and also covers how the vaccine works and its advantages and disadvantages.